Haoyu Lian
Nanning, 530021, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Correction: Periplogenin attenuates LPS-mediated inflammatory osteolysis through the suppression of osteoclastogenesis via reducing the NF-κB and MAPK signaling pathways.
Journal: Cell death discovery
Published: March 30, 2026
Significant association of RANKL polymorphisms with bone metastasis among patients with breast cancer.
Journal: Frontiers in oncology
Published: January 15, 2026
Schisandrol B inhibits osteoclastogenesis and mitigates estrogen deficiency-induced bone loss by targeting TRAF6-NOX1 pathway.
Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology
Published: October 20, 2025
MSDC-0160, a novel clinical-stage mitochondrial pyruvate carrier inhibitor, suppresses osteoclast differentiation and alleviates type 2 diabetes-related bone loss.
Journal: Journal of translational medicine
Published: September 16, 2025
Sinensetin serves as an AMPK activator to inhibit RANKL-induced osteoclastogenesis via osteoclast cytoskeleton reorganization.
Journal: Journal of translational medicine
Published: November 10, 2024
Rc3h1 negatively regulates osteoclastogenesis by limiting energy metabolism.
Journal: Theranostics
Published: June 13, 2024
Hecogenin alleviates LPS-induced osteolysis via regulating pyroptosis and ROS involved Nrf2 activation.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: February 28, 2024
Active fraction of Polyrhachis vicina (Rogers) inhibits osteoclastogenesis by targeting Trim38 mediated proteasomal degradation of TRAF6.
Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology
Published: January 02, 2024
Tussilagone inhibits osteoclastogenesis by modulating mitochondrial function and ROS production involved Nrf2 activation.
Journal: Biochemical pharmacology
Published: September 25, 2023
Cichoric acid targets RANKL to inhibit osteoclastogenesis and prevent ovariectomy-induced bone loss.
Cichoric acid targets RANKL to inhibit osteoclastogenesis and prevent ovariectomy-induced bone loss.
Journal: Phytotherapy research : PTR
Published: September 09, 2023
Periplogenin attenuates LPS-mediated inflammatory osteolysis through the suppression of osteoclastogenesis via reducing the NF-κB and MAPK signaling pathways.
Journal: Cell death discovery
Published: July 20, 2023
Myrislignan targets extracellular signal-regulated kinase (ERK) and modulates mitochondrial function to dampen osteoclastogenesis and ovariectomy-induced osteoporosis.
Journal: Journal of translational medicine
Published: April 07, 2023
Last Updated: 09/26/2026